Becton Dickinson Aktie - Fundamentalanalyse - Dividendenrendite KGV

Becton Dickinson (ISIN: US0758871091, WKN: 857675) Kursdatum: 18.05.2018 Kurs: 225,010 USD
Beschreibung Daten
Symbol BDX
Marktkapitalisierung 50.309.537.792,00 USD
Land Vereinigte Staaten von Amerika
Indizes S&P 500
Sektor Gesundheitswesen
Rohdaten nach US GAAP in Millionen USD
Aktiensplits 1998-08-21 - 2.0000/1.0000 | 1996-08-16 - 2.0000/1.0000 | 1993-03-01 - 2.0000/1.0000 | 1986-03-03 - 2.0000/1.0000 |
Internet www.bd.com
Letztes Bilanz Update 28.11.2017

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 18.05.2018
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
27,60 19,73 1,30% 2,73 34,31 48,92 4,16 3,89

Firmenbeschreibung

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women\'s health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Die Finanzoo GmbH übernimmt keine Haftung für die Richtigkeit der Angaben! Alle Angaben sind ohne Gewähr. Quellen: www.bundesanzeiger.de, www.sec.gov, www.bd.com